孕妇与非孕妇接种Tdap疫苗的反应原性与免疫原性比较
该观察性研究纳入374名孕妇和225名非孕妇接种Tdap疫苗,评估局部和全身反应及血清学应答。孕妇中重度注射部位疼痛报告率显著高于非孕妇(17.9% vs 11.1%),但未导致就医;既往接种Tdap未增加孕妇中重度反应。所有疫苗抗原抗体滴度接种后均升高,非孕妇百日咳毒素和丝状血凝素抗体滴度显著高于孕妇(p < 0.01)。
要点
- 孕妇接种Tdap后中重度注射部位疼痛报告率17.9%,非孕妇为11.1%,但未因此就医。
- 孕妇重复接种与首次接种Tdap相比,中重度局部或全身反应无显著增加。
- 接种后所有疫苗抗原抗体滴度均升高,非孕妇抗百日咳毒素和丝状血凝素滴度显著高于孕妇(p < 0.01)。
核心结论
- Tdap疫苗在孕妇和非孕妇中耐受性良好,孕妇注射部位中重度疼痛较非孕妇更常见但未导致就医,既往接种Tdap未增加孕妇中重度反应,所有抗原血清学应答均稳健。
研究设计与样本
- 观察性研究,纳入孕20-34周的孕妇374名和接受Tdap的非孕妇225名,接种后一周评估局部和全身反应,基线和接种后28天采用标准化酶联免疫吸附试验测定百日咳毒素、丝状血凝素、百日咳杆菌粘附素、菌毛、破伤风和白喉特异性IgG抗体滴度。
主要发现
- 严重局部或全身反应或「任何」发热不常见(两组均≤3%)。
- 孕妇中重度注射部位疼痛报告率17.9%,非孕妇为11.1%,差异显著,但未促使就医。
- 孕妇其他中重度或任何严重反应比例与非孕妇相比无显著升高。
- 孕妇重复接种与首次接种Tdap相比,中重度(包括疼痛)和严重反应无显著升高。
- 接种后所有疫苗抗原抗体滴度从基线升高;非孕妇接种后抗百日咳毒素和丝状血凝素抗体滴度显著高于孕妇(p < 0.01)。
临床怎么用
- 孕妇接种Tdap后中重度注射部位疼痛较非孕妇更常见,但未导致就医,既往接种Tdap不增加孕妇中重度反应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tetanus toxoid, reduced diphtheria toxoid, and acellular pertusiss (Tdap) vaccine is recommended during each pregnancy, regardless of prior receipt. Data on reactogenicity and immunogenicity, particularly after repeated Tdap, are limited. We compared local injection-site and systemic reactions and serologic response following Tdap in (1) pregnant and nonpregnant women and (2) pregnant women by self-reported prior Tdap receipt. STUDY DESIGN: Pregnant women (gestational age 20-34 weeks) and nonpregnant women receiving Tdap were enrolled in this observational study. Injection-site and systemic reactions were assessed for one week post-vaccination. Pertussis toxin, filamentous hemagglutinin, pertactin, fimbriae, tetanus and diphtheria specific IgG antibody titers were determined by standardized enzyme-linked immunosorbent assay at baseline and 28 days post-vaccination. Reactogenicity and serologic responses were compared by pregnancy status, and within pregnant women by self-reported prior Tdap receipt. RESULTS: 374 pregnant and 225 nonpregnant women were vaccinated. Severe local or systemic reactions or "any" fever were uncommon (≤3% for both groups). Moderate/severe injection-site pain was significantly higher in pregnant (17.9%) versus nonpregnant (11.1%) women, but did not prompt a healthcare visit. Proportions of other moderate/severe or any severe reactions were not significantly higher in pregnant compared to nonpregnant women. Moderate/severe (including pain) and severe reactions were not significantly higher in pregnant women receiving repeat versus first-time Tdap. Antibody titers increased from baseline to post-vaccination for all vaccine antigens in pregnant and nonpregnant women; post-vaccination titers against pertussis toxin and filamentous hemagglutinin were significantly higher in nonpregnant versus pregnant women (p < 0.01). CONCLUSION: Tdap was well-tolerated in pregnant and nonpregnant women. Pregnant women were more likely to report moderate/severe pain at the Tdap injection-site compared with nonpregnant women, but did not necessitate medical visits. Prior Tdap receipt did not increase occurrence of moderate/severe local or systemic reactions in pregnant women. Serologic responses to all vaccine antigens were robust. Clinical Trial Registration@ClinicalTrials.gov. NCT02209623. https://clinicaltrials.gov/ct2/show/NCT02209623.
引用
- Fortner KB, Swamy GK, Broder KR, et al. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women. Vaccine. 2018. PMID: 30219367. doi:10.1016/j.vaccine.2018.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。